Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight
- 12 January 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 119 (2), 612-618
- https://doi.org/10.1182/blood-2011-07-360594
Abstract
Comparison of the pharmacokinetics (PK) of a coagulation factor between groups of patients can be biased by differences in study protocols, in particular between blood sampling schedules. This could affect clinical dose tailoring, especially in children. The aim of this study was to describe the relationships of the PK of factor VIII (FVIII) with age and body weight by a population PK model. The potential to reduce blood sampling was also explored. A model was built for FVIII PK from 236 infusions of recombinant FVIII in 152 patients (1-65 years of age) with severe hemophilia A. The PK of FVIII over the entire age range was well described by a 2-compartment model and a previously reported problem, resulting from differences in blood sampling, to compare findings from children and adults was practically abolished. The decline in FVIII clearance and increase in half-life with age could be described as continuous functions. Retrospective reduction of blood sampling from 11 to 5 samples made no important difference to the estimates of PK parameters. The obtained findings can be used as a basis for PK-based dose tailoring of FVIII in clinical practice, in all age groups, with minimal blood sampling.Keywords
This publication has 26 references indexed in Scilit:
- Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophiliaHaemophilia, 2010
- Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimensJournal of Thrombosis and Haemostasis, 2010
- Kinetic evaluation of four Factor VIII concentrates by model-independent methodsScandinavian Journal of Haematology, 2009
- Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patientsJournal of Thrombosis and Haemostasis, 2008
- Pharmacokinetics of recombinant factor VIII (Kogenate‐FS®) in children and causes of inter‐patient pharmacokinetic variabilityHaemophilia, 2006
- Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspectiveHaemophilia, 2003
- Pharmacokinetics of Coagulation FactorsClinical Pharmacokinetics, 2001
- Improved cost‐effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia AHaemophilia, 1997
- Pharmacokinetics of Factor VIII in HumansClinical Pharmacokinetics, 1992
- Effect of height and weight on the in vivo recovery of transfused factor VIII C.Journal of Clinical Pathology, 1982